Cargando…
Translational precision medicine: an industry perspective
In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179706/ https://www.ncbi.nlm.nih.gov/pubmed/34090480 http://dx.doi.org/10.1186/s12967-021-02910-6 |
_version_ | 1783703843755786240 |
---|---|
author | Hartl, Dominik de Luca, Valeria Kostikova, Anna Laramie, Jason Kennedy, Scott Ferrero, Enrico Siegel, Richard Fink, Martin Ahmed, Sohail Millholland, John Schuhmacher, Alexander Hinder, Markus Piali, Luca Roth, Adrian |
author_facet | Hartl, Dominik de Luca, Valeria Kostikova, Anna Laramie, Jason Kennedy, Scott Ferrero, Enrico Siegel, Richard Fink, Martin Ahmed, Sohail Millholland, John Schuhmacher, Alexander Hinder, Markus Piali, Luca Roth, Adrian |
author_sort | Hartl, Dominik |
collection | PubMed |
description | In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective. |
format | Online Article Text |
id | pubmed-8179706 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81797062021-06-07 Translational precision medicine: an industry perspective Hartl, Dominik de Luca, Valeria Kostikova, Anna Laramie, Jason Kennedy, Scott Ferrero, Enrico Siegel, Richard Fink, Martin Ahmed, Sohail Millholland, John Schuhmacher, Alexander Hinder, Markus Piali, Luca Roth, Adrian J Transl Med Review In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective. BioMed Central 2021-06-05 /pmc/articles/PMC8179706/ /pubmed/34090480 http://dx.doi.org/10.1186/s12967-021-02910-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Hartl, Dominik de Luca, Valeria Kostikova, Anna Laramie, Jason Kennedy, Scott Ferrero, Enrico Siegel, Richard Fink, Martin Ahmed, Sohail Millholland, John Schuhmacher, Alexander Hinder, Markus Piali, Luca Roth, Adrian Translational precision medicine: an industry perspective |
title | Translational precision medicine: an industry perspective |
title_full | Translational precision medicine: an industry perspective |
title_fullStr | Translational precision medicine: an industry perspective |
title_full_unstemmed | Translational precision medicine: an industry perspective |
title_short | Translational precision medicine: an industry perspective |
title_sort | translational precision medicine: an industry perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179706/ https://www.ncbi.nlm.nih.gov/pubmed/34090480 http://dx.doi.org/10.1186/s12967-021-02910-6 |
work_keys_str_mv | AT hartldominik translationalprecisionmedicineanindustryperspective AT delucavaleria translationalprecisionmedicineanindustryperspective AT kostikovaanna translationalprecisionmedicineanindustryperspective AT laramiejason translationalprecisionmedicineanindustryperspective AT kennedyscott translationalprecisionmedicineanindustryperspective AT ferreroenrico translationalprecisionmedicineanindustryperspective AT siegelrichard translationalprecisionmedicineanindustryperspective AT finkmartin translationalprecisionmedicineanindustryperspective AT ahmedsohail translationalprecisionmedicineanindustryperspective AT millhollandjohn translationalprecisionmedicineanindustryperspective AT schuhmacheralexander translationalprecisionmedicineanindustryperspective AT hindermarkus translationalprecisionmedicineanindustryperspective AT pialiluca translationalprecisionmedicineanindustryperspective AT rothadrian translationalprecisionmedicineanindustryperspective |